Cargando…
Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product
Autores principales: | Niederwieser, Dietger, Hamm, Caroline, Cobb, Patrick, Mo, Mindy, Forsyth, Cecily, Tucci, Alessandra, Hanes, Vladimir, Delwail, Vincent, Hajek, Roman, Chien, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701060/ https://www.ncbi.nlm.nih.gov/pubmed/33180232 http://dx.doi.org/10.1007/s11523-020-00772-4 |
Ejemplares similares
-
Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product
por: Niederwieser, Dietger, et al.
Publicado: (2020) -
Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
por: Burmester, Gerd, et al.
Publicado: (2020) -
Yellow Jasmine
Publicado: (1861) -
The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
por: Goldschmidt, Jerome, et al.
Publicado: (2020) -
Analysis of Volatile Components of Jasmine and Jasmine Tea during Scenting Process
por: Zhang, Yangbo, et al.
Publicado: (2022)